Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $434.88, for a total transaction of $1,739,520.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at approximately $56,534.40. This represents a 96.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Up 2.2%

Shares of NASDAQ:UTHR opened at $453.07 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $455.12. The company’s 50-day moving average price is $356.31 and its two-hundred day moving average price is $319.01. The firm has a market cap of $20.44 billion, a P/E ratio of 17.68, a P/E/G ratio of 6.91 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the prior year, the company earned $5.85 EPS. The firm’s revenue was up 11.7% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on UTHR shares. Royal Bank Of Canada began coverage on shares of United Therapeutics in a report on Friday, September 26th. They set an “outperform” rating and a $569.00 price objective on the stock. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Finally, Morgan Stanley reduced their target price on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Ten investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $449.57.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Two Sigma Investments LP boosted its holdings in shares of United Therapeutics by 3.0% in the fourth quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 52 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of United Therapeutics by 15.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company’s stock valued at $1,991,000 after buying an additional 769 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of United Therapeutics by 84.7% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 4,297 shares of the biotechnology company’s stock valued at $1,325,000 after buying an additional 1,970 shares during the period. Curat Global LLC bought a new stake in shares of United Therapeutics in the first quarter worth $63,000. Finally, UMB Bank n.a. lifted its position in shares of United Therapeutics by 17.1% in the first quarter. UMB Bank n.a. now owns 1,289 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 188 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.